CLDN1 and hepatocellular carcinoma: Using an antibody raised against ECL1 of CLDN1 (OM-7D3-B3, Table 1) (41), researchers demonstrated specific binding to patient derived HCC cells compared to matched healthy tumor-adjacent tissue and showed efficacy against hepatoma cell lines in in vitro and ex vivo patient derived spheroid models including sorafenib- and nivolumab-resistant tumors (60).